title: Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease.
abstract: La Crosse virus (LACV) is the major cause of pediatric viral encephalitis in the United States; however, the mechanisms responsible for age-related susceptibility in the pediatric population are not well understood. Our current studies in a mouse model of LACV infection indicated that differences in myeloid dendritic cell (mDC) responses between weanling and adult mice accounted for susceptibility to LACV-induced neurological disease. We found that type I interferon (IFN) responses were significantly stronger in adult than in weanling mice. Production of these IFNs required both endosomal Toll-like receptors (TLRs) and cytoplasmic RIG-I-like receptors (RLRs). Surprisingly, IFN expression was not dependent on plasmacytoid DCs (pDCs) but rather was dependent on mDCs, which were found in greater number and induced stronger IFN responses in adults than in weanlings. Inhibition of these IFN responses in adults resulted in susceptibility to LACV-induced neurological disease, whereas postinfection treatment with type I IFN provided protection in young mice. These studies provide a definitive mechanism for age-related susceptibility to LACV encephalitis, where mDCs in young mice are insufficiently activated to control peripheral virus replication, thereby allowing virus to persist and eventually cause central nervous system (CNS) disease.
  
  
  OBJECTIVE
  La Crosse virus (LACV) is the primary cause of pediatric viral encephalitis in the United States. Although the virus infects both adults and children, over 80% of the reported neurological disease cases are in children. To understand why LACV causes neurological disease primarily in young animals, we used a mouse model where weanling mice, but not adult mice, develop neurological disease following virus infection. We found that an early immune response cell type, myeloid dendritic cells, was critical for protection in adult animals and that these cells were reduced in young animals. Activation of these cells during virus infection or after treatment with type I interferon in young animals provided protection from LACV. Thus, this study demonstrates a reason for susceptibility to LACV infection in young animals and shows that early therapeutic treatment in young animals can prevent neurological disease.
authors.affiliation: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
authors.forename: Katherine G
authors.initials: KG
authors.lastname: Taylor
authors.affiliation: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
authors.forename: Tyson A
authors.initials: TA
authors.lastname: Woods
authors.affiliation: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
authors.forename: Clayton W
authors.initials: CW
authors.lastname: Winkler
authors.affiliation: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
authors.forename: Aaron B
authors.initials: AB
authors.lastname: Carmody
authors.affiliation: Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA petersonka@niaid.nih.gov.
authors.forename: Karin E
authors.initials: KE
authors.lastname: Peterson
mesh_terms: D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D002490:Central Nervous System / Q000276:immunology* / Q000821:virology; D003713:Dendritic Cells / Q000276:immunology* / Q000821:virology; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D004670:Encephalitis, California / Q000276:immunology* / Q000401:mortality / Q000821:virology; D015870:Gene Expression / Q000276:immunology; D006801:Humans; D007271:Injections, Intradermal; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D007370:Interferon Type I / Q000235:genetics / Q000276:immunology; D018062:La Crosse virus / Q000276:immunology*; D051379:Mice; D022423:Myeloid Cells / Q000276:immunology* / Q000821:virology; D016019:Survival Analysis; D051193:Toll-Like Receptors / Q000235:genetics / Q000276:immunology; D014779:Virus Replication
chemical_list: D007370:Interferon Type I; D051193:Toll-Like Receptors